Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SNCA | P37840 | 8/20 | 0.51 |
| ▸ | CDK4 | P11802 | 4/20 | 0.47 |
| ▸ | CCND1 | P24385 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7223336 | 0.85 | SNCA (0.49) | MAPTSNCACDK4CCND1TRPV1 | |
| SCHEMBL7222956 | 0.85 | MAPT (0.55) | MAPTSNCACDK4CCND1TRPV1 | |
| SCHEMBL7857145 | 0.84 | CDK4 (0.47) | MAPTSNCACDK4CCND1PPARG | |
| SCHEMBL7225068 | 0.81 | SNCA (0.49) | MAPTSNCACDK4CCND1TRPV1 | |
| SCHEMBL7223614 | 0.81 | SNCA (0.50) | MAPTSNCACDK4CCND1TRPV1 | |
| SCHEMBL7231199 | 0.80 | SNCA (0.49) | MAPTSNCACDK4CCND1TRPV1 | |
| SCHEMBL7224298 | 0.80 | CDK4 (0.54) | MAPTSNCACDK4CCND1TRPV1 | |
| SCHEMBL7224390 | 0.80 | CDK4 (0.53) | SNCACDK4CCND1TRPV1 | |
| SCHEMBL7229562 | 0.79 | SNCA (0.46) | MAPTSNCACDK4CCND1TRPV1 | |
| SCHEMBL7231078 | 0.79 | MAPT (0.49) | MAPTSNCACDK4CCND1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | MAPT 4540/4885SNCA 2451/4885CDK4 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.